Ezrin在化疗敏感性不同大B细胞淋巴瘤中表达的实验研究

目的：比较化疗敏感性不同弥漫性大B细胞淋巴瘤的蛋白质表达差异,寻找可反映大B细胞淋巴瘤化疗敏感性的标志物。方法：通过肿瘤药物敏感试验选取化疗高敏感性和低敏感性大B细胞淋巴瘤组织,进行蛋白质组学比较研究后得出差异表达蛋白;对在高敏感组中高表达的埃兹蛋白（Ezrin）进一步行免疫印迹验证,应用免疫组化技术检测在临床病例中的表达情况。结果：建立了化疗高敏感和低敏感大B细胞淋巴瘤差异表达蛋白质凝胶2D图谱,鉴定了28种差异表达蛋白,发现Ezrin蛋白在化疗高敏感组表达高于低敏感组,免疫印迹和免疫组化结果也进一步证实了Ezrin的这一表达状态。结论：Ezrin蛋白表达在化疗敏感性不同大B细胞淋巴瘤中存在差别,可能作为预测淋巴瘤化疗敏感性的候选标志物。     

大B细胞性淋巴瘤化疗敏感性相关蛋白类型及信号通路的生物信息学研究

目的:筛选化疗敏感性不同大B细胞淋巴瘤中差异表达蛋白,并分析其类型和相关信号通路,为淋巴瘤化疗敏感性的研究提供重要的靶蛋白。方法:通过肿瘤药物敏感试验选取化疗高敏感性和低敏感性大B细胞淋巴瘤组织,进行蛋白质组学比较研究后得出差异表达蛋白;应用GO-分析软件对差异表达蛋白进行分类和关系分析。结果:将大B细胞淋巴瘤化疗高敏感组和化疗低敏感组蛋白质经二维凝胶电泳分离的差异表达蛋白通过质谱和生物信息学分析鉴定的蛋白点52个,按生化过程分为12种蛋白,其中与代谢过程有关的蛋白最多,其次是细胞过程蛋白;按信号通路分为20余条信号通路包括凋亡信号通路、细胞周期相关通路等。按分子功能分为9类蛋白,其中结合相关蛋白最多,其次是催化活性蛋白,第三为结构蛋白。按蛋白功能分为钙结合蛋白、水解酶、氧化还原酶、磷酸酶等。按细胞内定位分为细胞外区、细胞内、核糖核蛋白复合体三类蛋白,其中细胞内蛋白数量最多,其次是核糖核蛋白复合体。根据信号通路网络图,所有差异表达蛋白以三个复杂网络区为主和四个较为简单联系网络区。结论:大B细胞性淋巴瘤的化疗敏感性与多种蛋白功能和多条信号通路的改变有关,信号通路间也存在复杂的联系。     

cDNA阵列筛选结直肠癌化疗敏感性相关基因的初步研究

目的:筛选与结直肠癌中与化疗敏感性相关的基因,为结直肠癌化疗的个体化方案制定提供分子遗传学方面的依据.方法:收集结直肠癌新鲜组织标本,部分用于提取组织RNA和组织蛋白质,部分用于肿瘤药物敏感实验(MTT法).病理学诊断为中分化腺癌,根据药物敏感实验结果分为化疗高敏感组和化疗低敏感组,进行cDNA阵列实验比较筛选差异表达基因,Western Blot检测部分差异表达基因的表达情况.结果:通过肿瘤药物敏感实验结果得到对5-Fu+CF+L-OHP(氟脲嘧啶,亚叶酸钙,奥沙利铂)联合作用敏感的5例(高敏感组),不敏感的5例(低敏感组),cDNA阵列结果显示化疗高敏感组和低敏感组的差异表达基因其中有34个基因,其中差异表达显著的基因9个;叶酸多聚谷氨酸(FPGS)的表达在高敏感组中均高于低敏感组,HSP27在化疗低敏感组中的表达均高于高敏感组,与基因芯片中cDNA表达变化一致.结论:在结直肠腺癌化疗敏感性不同的病例中存在差异表达基因,这些基因可能成为结直肠癌化疗敏感性预测的生物标志物.     

应用蛋白质组学方法初步筛选与鼻咽癌放射敏感相关的蛋白

目的:通过筛选放射敏感性不同的鼻咽癌细胞中差异表达蛋白,以发现与鼻咽癌放射敏感相关的蛋白。方法:放射处理并结合流式细胞术检测及比较5-8F和6-10B细胞的放射敏感性。提取细胞总蛋白,进行双向凝胶电泳、MALDI-TOF肽质指纹图分析、质谱数据的蛋白质库搜寻鉴定。应用Western Blot检测细胞中蛋白质表达。应用免疫组织化学方法检测鼻咽癌组织中相关蛋白的表达。结果:双向凝胶电泳后对胶上的部分分辨较好的差异蛋白质点进行肽质谱指纹图分析和鉴定,在两种细胞中差异表达最为显著的蛋白质有9个。Western Blot证实CK19和P73在5-8F和6-10B表达与蛋白质组结果一致。P73在鼻咽癌放射敏感组和不敏感组中的表达阳性率分别为90%、57.5%,存在显著性差异。结论:放射敏感性不同的鼻咽癌细胞中存在一些差异表达蛋白,这些蛋白可能与鼻咽癌放射敏感性有关,其中P73可能成为放射敏感性预测的侯选标志物。     

Galectin-7、S100A9、NMP238在放疗敏感性不同宫颈癌组织中的表达及意义

目的:观察S100A9、Galectin7、NMP238在放疗敏感性不同宫颈癌组织中的表达及意义。方法:收集治疗前宫颈癌组织标本,病理诊断均为中分化鳞癌,在进行放疗后,根据WHO实体瘤放疗疗效判断标准,从中选择60例对放疗敏感的病例(高敏感组)和35例对放疗不敏感的病例(低敏感组),应用免疫组织化学方法检测组织中这些蛋白的表达。结果:免疫组化结果显示S100A9、Galectin7的表达强度和表达率在高敏感组中均高于低敏感组,NMP238在低敏感组中的表达强度及表达率高于高敏感组。结论:S100A9、Galectin7和NMP238与宫颈癌放疗敏感性有关。     

弥漫性大B细胞淋巴瘤hs-CRP和VEGF的表达及与化疗耐药的相关性

目的:研究弥漫性大B细胞淋巴瘤超敏C-反应蛋白(hs-CRP)和血管内皮生长因子(VEGF)的表达及与化疗耐药的相关性。方法:选取2013年11月到2014年11月我院收治的化疗耐药弥漫性大B细胞淋巴瘤25例(A组),化疗敏感弥漫性大B细胞淋巴瘤25例(B组),另选取同期健康者25例(C组)。应用免疫荧光法检测三组入选者的hs-CRP,及酶联免疫吸附法试验(ELISA)法检测VEGF。结果:化疗前A组hs-CRP、VEGF水平显著高于B组和C组,B组高于C组,比较差异具有统计学意义(P0.05);化疗缓解后A组和B组hs-CRP、VEGF水平与化疗前比显著降低,差异有统计学意义(P0.05),但两组间比较差异无统计学意义(P0.05);A组复发耐药后hs-CRP、VEGF水平与缓解后比显著升高,差异具有统计学意义(P0.05)。结论:弥漫性大B细胞淋巴瘤血清中hs-CRP、VEGF水平改变与病情变化有关,可能与化疗耐药有关。     

LaminB1、NMP238表达与宫颈癌放疗敏感性的相关性研究

目的:观察LaminB1、NMP238在放疗敏感性不同宫颈癌组织中的表达及意义.方法:收集治疗前宫颈癌组织标本,病理诊断均为中分化鳞癌,在进行放疗后,根据WHO实体瘤放疗疗效判断标准,从中选择40例对放疗敏感的病例(高敏感组)和40例对放疗不敏感的病例(低敏感组),应用分子原位杂交方法检测组织中这些蛋白的表达.结果:免疫组化结果显示LaminB1,NMP238的阳性表达率在高敏感组中均低于低敏感组,LaminB1和NMP238表达具有显著相关性.结论:LaminB1、NMP238表达与宫颈癌放疗敏感性有关.     

卵巢高/低级别浆液性癌的定量蛋白质组学比较研究

目的:探讨卵巢高级别浆液性癌和低级别浆液性癌的差异表达蛋白,为阐明卵巢癌发生机制及寻找诊断和预后标志物的提供线索。方法:收集卵巢癌新鲜组织标本冻存于液氮中,经病理学确诊为高级别浆液性癌和低级别浆液性癌,两种类型各收集15例。应用i TRAQ定量蛋白质组学技术筛选及鉴定高/低级别浆液性癌的差异表达蛋白,并进行生物信息学分析。结果:卵巢高级别和低级别浆液性癌组织的定量蛋白质组学比较研究鉴定出差异表达蛋白314个,其中与低级别浆液性癌组比较,高级别浆液性癌组上调蛋白有97种,下调蛋白有217种。GO分析显示这些差异蛋白在分子功能、生物学功能、细胞成分方面均具有一定分布特点。KEGG分析显示这些差异蛋白涉及复杂的信号通路。结论:高/低级别浆液性癌之间存在差异表达蛋白,这些蛋白涉及复杂的功能和信号通路可能在两型卵巢癌发生机制及肿瘤生物学行为差异中具有重要意义。     

卵巢癌中HMGB1、BRCA1和p62蛋白的表达与其化疗敏感性的相关性

为了探讨卵巢癌中HMGB1、BRCA1和p62蛋白的表达与化疗敏感性的相关性,培养卵巢癌顺铂化疗耐药细胞ES-2和敏感细胞SKVO3,顺铂100 mg/m2环境培养5 d,分别采用Western blotting法和RT-PCR方法检测两种细胞中的HMGB1、BRCA1和p62蛋白表达情况,采用流式细胞术测算细胞凋亡率。敏感组细胞SKOV3和耐药组细胞ES-2中,BRCA1蛋白表达率分别为(38.08±22.56)%和(45.65±22.42)%,HMGB1蛋白表达率分别为(75.13±16.45)%和(83.08±24.22)%,p62蛋白表达率分别为(52.31±25.13)%和(37.26±21.09)%;顺铂处理后,敏感组SKOV3细胞中BRCA1蛋白表达量显著提高(p0.05),耐药组ES-2细胞中p62蛋白相对表达量高于敏感组SKOV3细胞(p0.01)。卵巢癌化疗后HMGB1下调与BRCA1、p62上调共存;卵巢癌中BRCA1蛋白的不同表达与化疗敏感性相关,其水平变化有可能作为一种新的肿瘤标志物,动态观察卵巢癌病情进展,为临床治疗提供客观指标。     

同时放化疗敏感性不同宫颈癌组织的二维电泳图谱建立及质谱分析

目的:分析同时放化疗后高敏感和低敏感中晚期宫颈癌组织之间蛋白质组的差异,为确定宫颈癌同时放化疗敏感性相关蛋白提供依据。方法:收集治疗前的中晚期宫颈癌活检组织标本,均为中分化鳞癌,置于—80℃超低温冰箱保存。同时放化疗后,根据WHO实体瘤疗效判断标准,将收集的10例宫颈癌组织标本分为高敏感组(5例)和低敏感组(5例);提取组织总蛋白,进行双向凝胶电泳(two-dimensional gel electrophoresis,2-DE)得到凝胶图谱,采用PD-quest 7.0软件进行匹配和差异分析,识别两组之间表达差异蛋白点。将部分差异蛋白点进行胶内原位酶解后进行MALDI-TOF-MS分析,获取肽质量指纹图,数据库搜索鉴定蛋白质。结果:建立了分辨率高,重复性好的同时放化疗后宫颈癌组织高敏感组和低敏感组的双向凝胶电泳图谱。高敏感组蛋白点数为781±74个,低敏感组蛋白点数为766±52个,组间平均匹配率为87.6%。质谱分析成功鉴定15个差异表达蛋白,其中7个蛋白质在高敏感组高表达,8个蛋白质在高敏感组低表达。结论:蛋白质2-DE图谱和质谱鉴定结果说明同时放化疗后高敏感组和低敏感组宫颈癌组织间存在蛋白质表达的差异,这些蛋白质可能与同时放化疗敏感性有关。     

鼻NK／T细胞淋巴瘤间质清道夫受体A的表达及意义

目的 观察清道夫受体A（scavenger receprorA,SR-A）在鼻NK／T细胞淋巴瘤间质中的表达,探讨其意义。方法 对鼻NK／T细胞淋巴瘤,鼻B细胞淋巴瘤以及鼻部炎症的石蜡标本进行HE染色和SP免疫组织化学染色检测SR-A的表达。结果 SR-A蛋白在鼻NK／T细胞淋巴瘤,鼻B细胞淋巴瘤和鼻部炎症中阳性率分别为92．7％,29．2％和6．25%。统计学分析发现,鼻NK／T细胞淋巴瘤中SR-A的表达与B细胞淋巴瘤和炎症中SR-A的表达均有显著差异（P〈0．001）。结论 SR-A可能在鼻NK／T细胞淋巴瘤的诊断及鉴别诊断中有一定的参考价值。     

High SEPT9_i1 Protein Expression Is Associated with High-Grade Prostate Cancers

Septins are a family of GTP-binding cytoskeleton proteins expressed in many solid tumors. Septin 9 (SEPT9) in particular was found overexpressed in diverse carcinomas. Herein, we studied the expression of SEPT9 isoform 1 protein (SEPT9_i1) in human prostate cancer specimens. We utilized immunohistochemical staining to study the expression of SEPT9_i1 protein. Staining level was analyzed in association with clinical characteristics and the pathological Gleason grade and score. Fifty human prostate cancer specimens (42 primary tumors and 8 metastatic lesions) were stained by SEPT9_i1 antibody and analyzed. SEPT9_i1 protein was expressed in prostate cancer cells but absent in normal epithelial cells. The intensity of staining was correlated proportionally to pretreatment prostate-specific antigen (PSA) blood levels and Gleason score (P < 0.05). SEPT9_i1 was highly expressed in all metastatic lesions. A significant assocation between SEPT9_i1 expression and high Gleason score on multivariate linear regression analysis was found. We conclude that SEPT9_i1 is expressed in high-grade prostate tumors suggesting it has a significant role in prostate tumorigenesis and that it could serve as a molecular marker for prostate tumor progression.     

Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells

The molecular chaperone heat shock protein 90 (Hsp90) affects the function of many oncogenic signaling proteins including nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expressed in anaplastic large cell lymphoma (ALCL). While ALK-positive ALCL cells are sensitive to the Hsp90 inhibitor and the geldanamycin (GA) analog, 17-allylamino-17-demethoxygeldanamycin (17-AAG), the proteomic effects of these drugs on ALK-positive ALCL cells are unpublished. In this study, we investigated the cellular, biologic, and proteomic changes occurring in ALK-positive ALCL cells in response to GA treatment. GA induced G2/M cell cycle arrest and caspase-3-mediated apoptosis. Furthermore, quantitative proteomic changes analyzed by cleavable isotope-coded affinity tag-LC-MS/MS (cICAT-LC-MS/MS) identified 176 differentially expressed proteins. Out of these, 49 were upregulated 1.5-fold or greater and 70 were downregulated 1.5-fold or greater in GA-treated cells. Analysis of biological functions of differentially expressed proteins revealed diverse changes, including induction of proteins involved in the 26S proteasome as well as downregulation of proteins involved in signal transduction and protein and nucleic acid metabolism. Pathway analysis revealed changes in MAPK, WNT, NF-kappaB, TGFbeta, PPAR, and integrin signaling components. Our studies reveal some of the molecular and proteomic consequences of Hsp90 inhibition in ALK-positive ALCL cells and provide novel insights into the mechanisms of its diverse cellular effects.     

Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line

The existence of several model systems with which to investigate a particular disease is advantageous for researchers. This is especially true for ovarian cancer, which, due to its complex and heterogeneous nature, inherently requires a large number of model systems. Here, we report a new ovarian serous adenocarcinoma cell line, designated YDOV-157, and characterized via post genomics and post proteomics. In this study, primary culture of tumor cells from ascites was performed and the cells were immortalized up to at least 60 passages in vitro. We studied the morphologies, cell proliferation, BRCA1/2 mutations, tumorigenesis capacity, and chemosensitivity of YDOV-157. Using a cDNA microarray, differentially expressed genes were identified and some of them were validated. Using proteomic analysis, we identified proteins that were differentially expressed in YDOV-157. The newly derived cell line, designated YDOV-157, grew as a monolayer and the doubling time was 102 h. When transplanted into nude mice, it initiated the formation of tumor masses with microscopic findings identical to those of the primary tumor. Chemosensitivity test showed that paclitaxel induced the highest chemosensitivity index. In microarray analysis, 2,520 probes were differently expressed, compared to human ovarian surface epithelial cells (HOSEs). In SYBR Green real-time PCR, the expression of E2F2 (P = 0.040) and CRABP2 genes (P = 0.030) was significantly higher in the ovarian cancer cell lines than in HOSEs. Furthermore, proteomic analysis showed that expression of 28 spots was significantly altered between YDOV-157 and HOSE. In conclusion, the newly derived YDOV-157 cell line may be an important research resource for studying cancer cell biology and should also be very useful for developing new strategies that inhibit cancer cell growth and progression.     

应用蛋白质组学技术筛选宫颈癌临床分期相关蛋白

目的：通过比较早期宫颈癌和中一晚期宫颈癌的差异表达蛋白,以发现与宫颈癌临床分期相关蛋白,为临床预后和复发的预测提供新指标。方法：收集早期宫颈癌和中一晚期宫颈癌组织标本,提取组织总蛋白进行二维凝胶电泳,选择部分差异表达蛋白进行MALDI—TOF质谱分析和生物信息学分析进行蛋白质鉴定,进一步应用WestemBlot和免疫组织化学技术检测部分差异表达蛋白的表达情况。结果：建立了早期宫颈癌组和中一晚期宫颈癌组的二维凝胶电泳图谱,其中两组的平均蛋白质点数分别为1098±23、1142±21,通过进行质谱分析和生物信息学查询,与早期宫颈癌组比较,鉴定了在中一晚期组下调的蛋白4个。包括HemoglobinsubunitbetaHB、caspase-14、galectin-7、CK19;中-晚期组上调的蛋白8个,包括NMP238、HSP70、Calmodulin-like5、S100A9。WesternBlot和免疫组化检测结果均显示S100A9在中-晚期组中的表达高于早期组,CK19在早期组中的表达高于中-晚期组。结论：早期宫颈癌和中-晚期宫颈癌中存在着差异表达蛋白,这些蛋白可能成为宫颈癌预后和复发预测的生物标志物。